APGE supply chain intelligence for Apogee Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GUGGENHEIM-SECURITIES-LLC | GUGGENHEIM-SECURITIES-LLC | 90% | On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,… |
| JEFFERIES-LLC | JEFFERIES-LLC | 90% | On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,… |
| SAMSUNG-BIOLOGICS | SAMSUNG-BIOLOGICS | 90% | For the three months ended March 31, 2026 and 2025, the Company recognized $ 0.4 million and $ 1.7 million, respectively, of research and development expense in connection with the Samsung Biologics MSA. |
| STIFEL-NICOLAUS-COMPANY-INCORPORATED | STIFEL-NICOLAUS-COMPANY-INCORPORATED | 90% | On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 90% | On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,… |
| SAMSUNG | SAMSUNG | 80% | the PSA provides for Samsung to receive compensation, including for contractually obligated expenses, and an exit fee in the high single-digit millions. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANNAPURNA-AGGREGATOR-L-P | ANNAPURNA-AGGREGATOR-L-P | 92% | Pursuant to the Revenue Share Agreement, in exchange for an upfront payment of $100.0 million (the "Tranche 1 Funding"), BXLS purchased from the Company the right to receive tiered revenue share paym… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| APGE-DEBT | Debt stack $8.0M | 90% | Market cache reports total debt of $8.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| APGE-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 231 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| GRDX | GridAI Technologies Corp. | 100.00 | 2 |